GlyProVac ApS: Financial statements 2019
CVR: 39724758
Source: annual report 2019, Danish Business Authority
03/07/2018 – 30/06/2019
GlyProVac ApS (CVR 39724758) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK 145,314 and a net result of DKK -917,733. Equity in the 2019 report amounted to DKK 1,370,867. The solvency ratio was 52.8%. The company had 2 employees in the financial year.
- Gross Profit
- DKK 145,314
- Profit/Loss
- DKK -917,733
- Equity
- DKK 1,370,867
- Total Assets
- DKK 2,594,444
- Employees
- 2
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
As of January 29, 2019, Kirsten Winther has joined the board of directors of GlyProVac ApS.
As of January 25, 2019, Peter Smedegaard has left the board of directors of GlyProVac ApS.
About GlyProVac ApS
GlyProVac ApS is a Danish company of the type Anpartsselskab based in Odense SØ, founded in 2018. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Anders Boysen and Ann Zahle Andersen. The board consists of Ann Zahle Andersen (chair), Allan Rosetzsky, Kirsten Winther and Willem Adriaan de Jongh. The company's owners include Bente Kristiansen, Rossi Finans ApS and I/S Rødeledsvej. The company has 3 employees (2026). In 2025, the company reported a gross profit of DKK -2,128,863 and a net result of DKK -5,168,999 compared with DKK -3,014,952 the year before. Equity in the 2025 report amounted to DKK -831,720.